{"url_path":"/sec/nnvc/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1379006/0001104659-26-061499-index.html","accession_number":"0001104659-26-061499","cik":"0001379006","ticker":"NNVC","issuer_name":"NANOVIRICIDES, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1379006/0001104659-26-061499-index.html","primary_entity_key":"0001379006","primary_entity_name":"NANOVIRICIDES, INC."},"word_count":191,"has_tables":true,"body_markdown":"**ITEM 6. EXHIBITS**\n\n**Exhibit No.**\n\n  ​ ​ ​\n\n**Description**\n\n \n\n \n\n \n\n31.1\n\n \n\n[Rule 13(a)-14(a)/15(d)-14(a) Certification of Chief Executive Officer](nnvc-20260331xex31d1.htm)\n\n \n\n \n\n \n\n31.2\n\n \n\n[Rule 13(a)-14(a)/15(d)-14(a) Certification of Chief Financial Officer](nnvc-20260331xex31d2.htm)\n\n \n\n \n\n \n\n32.1\n\n \n\n[Section 1350 Certification of Chief Executive Officer](nnvc-20260331xex32d1.htm)\n\n \n\n \n\n \n\n32.2\n\n \n\n[Section 1350 Certification of Chief Financial Officer](nnvc-20260331xex32d2.htm)\n\n \n\n \n\n \n\n101.INS\n\n \n\nInline XBRL Instance Document\n\n \n\n \n\n \n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema Document\n\n \n\n \n\n \n\n101.CAL\n\n \n\nInline XBRL Taxonomy Extension Calculation Linkbase Document\n\n \n\n \n\n \n\n101.DEF\n\n \n\nInline XBRL Taxonomy Extension Definition Linkbase Document\n\n \n\n \n\n \n\n101.LAB\n\n \n\nInline XBRL Taxonomy Extension Label Linkbase Document\n\n \n\n \n\n \n\n101.PRE\n\n \n\nInline XBRL Taxonomy Extension Presentation Linkbase Document\n\n​\n\n​\n\n​\n\n104\n\n​\n\nCover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit)\n\n​\n\n​\n\n​\n\n55\n\n[Table of Contents](#TOC)\n\n**SIGNATURES**\n\nPursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\n**NANOVIRICIDES, INC.**\n\n \n\n \n\n \n\n/s/ Anil R. Diwan\n\nDated: May 14, 2026\n\nName:\n\nAnil R. Diwan\n\n \n\nTitle:\n\nPresident, Chairman of the Board\n\n \n\n(Principal Executive Officer)\n\n \n\n \n\n \n\n/s/ Meeta Vyas\n\nDated: May 14, 2026\n\nName:\n\nMeeta Vyas\n\n \n\nTitle:\n\nChief Financial Officer\n\n \n\n(Principal Financial Officer)\n\n​\n\n​\n\n56"}